No final FDA approval for a generic Wegovy injection or tablet was identified in the U.S. records we checked on October 10, 2026. Semaglutide is the active ingredient's name; that name alone does not establish that a product is an approved generic Wegovy. Our check used the FDA Orange Book data and complete Drugs@FDA records, last updated October 9.
That answer leaves several useful questions: what does “generic” mean on an advertisement, does the Wegovy pill change the answer, and what should you ask a pharmacist before accepting a product? This guide separates those questions and gives you a product-verification worksheet. It covers U.S. approval records, not another country's rules or a pharmacy's live inventory.
Is there a generic Wegovy in the United States?
The records checked did not identify a generic with final FDA approval for either Wegovy form. We also checked FDA's authorized-generics list, dated October 5, 2026, and found no Wegovy entry. An authorized generic is marketed under the original brand's approval application, rather than a separate generic application. That list is updated quarterly from manufacturer reports, so it is an additional check, not a real-time stock report.
Do not read “no approved generic identified” as “no generic development exists.” The distinction matters because preliminary regulatory actions can appear in news and search results before a product has final approval.
What about the tentative semaglutide approval?
FDA's complete Drugs@FDA data files contain semaglutide application ANDA 220314, Apotex Inc., with tentative approval dated April 7, 2026. Its product records show “None (Tentative Approval).” The checked record does not establish that its reference brand is Wegovy, so we do not describe this application as generic Wegovy.
FDA's glossary explains that tentative approval does not allow the applicant to market the generic drug. Final approval and actual pharmacy availability are separate questions. The Orange Book Preface explains why tentatively approved products are excluded from its approved-product listing. Finding a tentative application in Drugs@FDA and none in the Orange Book is therefore not a contradiction.
What is the generic name for Wegovy?
Semaglutide is the active ingredient in Wegovy. In everyday conversation, “generic name” often means that ingredient name. An FDA-approved generic version means a specific finished drug product that has completed the relevant approval pathway. Those are different claims.
FDA's generic-drug questions and answers describes the requirements for an approved generic, including the active ingredient, strength, form and route, and the applicable labeling. An advertisement using the word semaglutide does not supply that product-specific evidence. Nor does sharing an ingredient make two branded medicines interchangeable for every use.
Ask your dispensing pharmacist to help you match the ingredient, product name and pharmacy fields on your own packaging to the prescribed product.
Is the Wegovy pill a generic?
No. Wegovy tablets are a branded oral form. The current Wegovy prescribing information, revised June 2026, covers both injection and oral tablets. A new form of a brand is not proof that a generic version has been approved.
The FDA records identify Wegovy injection under NDA 215256 and Wegovy tablets under NDA 218316. Those application numbers help match the correct product and route. They are not instructions for switching between the forms.
| Product or wording you see | What it establishes | What it does not establish |
|---|---|---|
| Wegovy injection, NDA 215256 | A specific branded injectable product record | Approval of an oral or compounded product |
| Wegovy tablets, NDA 218316 | A specific branded oral product record | Approval of a generic Wegovy tablet |
| “Semaglutide” in an advertisement | A claimed ingredient name | Identity, approval or equivalence of the finished product |
| A tentative ANDA action | A preliminary FDA regulatory status | Permission to market the generic product |
| An NDC number | A product-identification listing | FDA approval by itself |
The last distinction comes directly from FDA's National Drug Code Directory explanation: assignment of an NDC does not establish FDA approval. A number printed on a label is a starting point for checking identity, not the end of the check.
Is compounded semaglutide generic Wegovy?
No. Compounded drugs are not FDA-approved. A compounded semaglutide preparation is not an FDA-approved generic Wegovy. FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. Compounding and generic-drug approval are different processes; a prescription or a pharmacy license does not convert a compounded preparation into an approved generic.
FDA also distinguishes semaglutide sodium and semaglutide acetate from the active ingredient used in approved drugs. These salt names should not be treated as interchangeable simply because an advertisement shortens them to semaglutide. See FDA's concerns with unapproved GLP-1 drugs.
This distinction is about product identity and evidence. It does not determine whether a particular compounded prescription meets applicable requirements or is appropriate for an individual. Those questions need the prescribing clinician and dispensing pharmacist. Our separate guide explains what FDA approval means for compounded semaglutide.
When will generic Wegovy be available?
The checked records do not establish a confirmed U.S. launch date. A patent expiration date, a pending application, litigation news or tentative approval does not by itself tell you when a particular product will receive final approval and reach a pharmacy.
In July 2026, FDA published revised draft recommendations for certain generic peptide products, including Wegovy injection. These recommendations concern development and assessment of generic applications. They are not an approval announcement, and the injectable guidance does not establish approval of a generic tablet.
Treat a launch-year prediction as a forecast until an applicable final FDA action and product availability can be verified. Approval is one question; whether your pharmacy can dispense that exact product today is another. No future price is established by the absence or existence of a tentative application.
A worksheet for checking a “generic Wegovy” offer
Use this privately with your prescriber or pharmacist. You can copy it into your notes or print the page. It is a question list, not a self-certification tool; a completed table does not prove that a product is suitable for you.
| Record this detail | Ask this question |
|---|---|
| Exact product name and manufacturer or compounder | What finished product would actually be dispensed? |
| Form, route and presentation shown on the label | Is this an oral tablet or injectable product, and which FDA record matches it? |
| Full ingredient wording and any additions | Is the ingredient semaglutide, a named salt or a compounded mixture? |
| FDA application, product record, action and date checked | Is there final approval for this exact product, rather than tentative approval or only an NDC? |
| Any authorized-generic claim | Which original NDA and manufacturer information support that claim? |
| Dispensing pharmacy's name, U.S. address, phone and state license | Can I verify the pharmacy independently and speak with its licensed pharmacist? |
| Written directions, storage information and expiration or beyond-use date | Who will resolve a discrepancy between the prescription, packaging and instructions? |
| Current dispensing availability | Can this pharmacy supply the exact prescribed product now? |
FDA's online-pharmacy guidance identifies basic checks: a valid prescription requirement, a U.S. address and phone number, a licensed pharmacist and state-board licensure. Confirm the actual dispensing pharmacy rather than relying on an advertising badge or copied pharmacy name. An attractive website does not establish product approval or pharmacy identity.
If the product identity, FDA status or dispensing pharmacy cannot be verified, ask your pharmacist and prescriber to resolve the discrepancy before making a treatment decision. This article supplies no dose conversion, injection-unit calculation or substitution schedule.
What if cost is the reason you are searching?
Bring the exact prescribed product, your plan's coverage answer and the pharmacy's current written quote to the conversation. Ask which costs apply to that product and whether any assistance terms apply to your situation. Keep product approval and affordability as separate checks: a discount does not establish that an advertised generic exists.
For the price and coverage questions, use our Wegovy cost guide, check the date on it and confirm current terms with the manufacturer, plan and pharmacy. This approval-status article does not promise a future generic price or recommend a replacement medicine. Your clinician can discuss suitable treatment options if the prescribed product is difficult to obtain.
Educational information for U.S. readers, based on FDA records and sources checked October 10, 2026. Approval status and pharmacy availability can change. Decisions about treatment, substitution and an individual prescription belong with your licensed prescriber and pharmacist.
Frequently Asked Questions
Is there a generic Wegovy in the United States?
No final FDA approval for a generic Wegovy injection or tablet was identified in the records checked October 10, 2026, including complete Drugs@FDA data updated October 9. The dated authorized-generics list also had no Wegovy entry. These are approval-record checks, not a live report of pharmacy inventory.
What is the generic name for Wegovy?
Semaglutide is the active ingredient name. That does not mean every product advertised as semaglutide is an FDA-approved generic Wegovy. Approval must be checked for the specific finished product, form and route.
Does the tentative semaglutide approval mean generic Wegovy is available?
No. ANDA 220314 has tentative approval, which FDA explains does not allow marketing of the generic product. The checked application record does not establish Wegovy as its reference brand. It therefore does not establish an approved, available generic Wegovy.
Is the Wegovy pill a generic version?
No. The oral tablets are a branded form of Wegovy, separately identified in FDA application records from its injection. A branded tablet is not proof that a generic tablet has received final approval, and it does not supply switching instructions.
Is compounded semaglutide generic Wegovy?
No. Compounded drugs are not FDA-approved. Compounded semaglutide is not an FDA-approved generic Wegovy. FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. Questions about an individual compounded prescription require the prescriber and dispensing pharmacist.
When will generic Wegovy be available, and how much will it cost?
The checked FDA records do not establish a confirmed U.S. launch date or future price. A patent date, tentative application or draft guidance is not final approval or evidence of current pharmacy availability. Ask your pharmacist to verify the exact product and the latest FDA action.
Sources
This article is based on the following primary sources. Links open the original documents.
- 1.FDA Orange Book data files · U.S. Food and Drug Administration · accessed
- 2.Complete Drugs@FDA data files, data updated October 9, 2026 · U.S. Food and Drug Administration · accessed
- 3.FDA authorized generic drugs list, dated October 5, 2026 · U.S. Food and Drug Administration · accessed
- 4.Drugs@FDA glossary: tentative approval and application numbers · U.S. Food and Drug Administration · accessed
- 5.Orange Book Preface: tentatively approved products · U.S. Food and Drug Administration · accessed
- 6.FDA generic drugs questions and answers · U.S. Food and Drug Administration · accessed
- 7.Wegovy prescribing information, revised June 2026 · Novo Nordisk · accessed
- 8.FDA National Drug Code Directory: listing does not establish approval · U.S. Food and Drug Administration · accessed
- 9.FDA concerns with unapproved GLP-1 drugs · U.S. Food and Drug Administration · accessed
- 10.FDA draft product-specific guidance announcement, July 28, 2026 · U.S. Food and Drug Administration · accessed
- 11.FDA internet pharmacy warning letters and safe pharmacy checks · U.S. Food and Drug Administration · accessed
Telehealth prescribing rules differ by state. Read the state-by-state guide.
Majesta Health articles are written against primary sources (FDA labeling, NIH and CDC publications, state statutes) and each one passes a documented compliance review before publication. Where an article cites external sources, they are listed at the end of that article so you can check them yourself. No article currently carries an individual physician review; when a physician reviews an article, that page will show the reviewer's name, NPI and review date.
- Written against primary sources: FDA labeling and safety communications, NIH and CDC publications, state statutes and medical board rules
- Documented compliance review against FDA, FTC and LegitScript requirements before publication
- External sources, where an article cites them, are listed at the end of that article with links to the original documents
- Compounded medications are described as not FDA-approved as final products on every page that mentions them